

AMENDMENTS TO THE CLAIMS

Please enter the following amendments without prejudice or disclaimer.

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the claims

Claims 1-13 (Canceled)

Claim 14 (Currently Amended): An isolated apo-B100 protein comprising a proteoglycan receptor⁺ mutation in Site B, wherein Site B is equivalent to amino acids from about 3358 to about 3369 of the human apo-B100 protein and wherein the mutation comprises at least one amino acid substitution or deletion of at least one of Lys₃₃₆₃, Arg₃₃₆₂, or Arg₃₃₆₄.

Claims 15-17 (Canceled)

Claim 18 (Previously presented): The apo-B100 protein according to claim 14, wherein said mutation in Site B is at position 3363 and the lysine residue is replaced with a glutamic acid residue, and the amino acid sequence from position 3358 to 3367 is:

Thr₃₃₅₈-Arg₃₃₅₉-Leu₃₃₆₀-Thr₃₃₆₁-Arg₃₃₆₂-**Glu**₃₃₆₃-Arg₃₃₆₄-Gly₃₃₆₅-Leu₃₃₆₆-Lys₃₃₆₇ (SEQ ID NO:1).

Claim 19 (Previously presented): A polypeptide comprising the amino acid sequence of Site B in the apo-B100 protein according to claim 14, wherein said Site B is flanked on at least one side by a contiguous sequence of at least 10 amino acids which is directly adjacent to Site B in the wild-type human apo-B100 sequence.

Claim 20 (Previously presented): An LDL particle comprising an apo-B100 protein according to claim 14.

Claims 21-28 (Canceled)